Epizyme Inc. [EPZM] Is Currently -14.41 below its 200 Period Moving Avg: What Dose This Mean?

Epizyme Inc. [NASDAQ: EPZM] closed the trading session at $12.30 on 08/04/20. The day’s price range saw the stock hit a low of $12.285, while the highest price level was $14.37. The company report on August 4, 2020 that Epizyme Reports Business Progress and Second Quarter 2020 Financial Results.

TAZVERIK® Approved for Multiple Cancer Indications; Executing Well on Commercial Launches for TAZVERIK in Epithelioid Sarcoma and Follicular Lymphoma.

Conference Call to be Held Today, August 4 at 8:30 a.m. ET.

The stocks have a year to date performance of -50.00 percent and weekly performance of -15.00 percent. The stock has been moved at -43.11 percent over the last six months. The stock has performed -22.20 percent around the most recent 30 days and changed -32.68 percent over the most recent 3-months.

If compared to the average trading volume of 1.18M shares, EPZM reached to a volume of 3189546 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Epizyme Inc. [EPZM]:

Oppenheimer have made an estimate for Epizyme Inc. shares, keeping their opinion on the stock as Perform, with their previous recommendation back on April 01, 2020. While these analysts kept the previous recommendation, Barclays raised their target price to Overweight. The new note on the price target was released on March 04, 2020, representing the official price target for Epizyme Inc. stock. Previously, the target price had yet another raise from $25 to $36, while H.C. Wainwright kept a Buy rating on EPZM stock.

The Average True Range (ATR) for Epizyme Inc. is set at 0.88, with the Price to Sales ratio for EPZM stock in the period of the last 12 months amounting to 72.73. The Price to Book ratio for the last quarter was 4.03, with the Price to Cash per share for the same quarter was set at 3.68.

EPZM stock trade performance evaluation

Epizyme Inc. [EPZM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -15.00. With this latest performance, EPZM shares dropped by -22.20% in over the last four-week period, additionally sinking by -43.11% over the last 6 months – not to mention a rise of 9.43% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EPZM stock in for the last two-week period is set at 29.83, with the RSI for the last a single of trading hit 24.17, and the three-weeks RSI is set at 32.56 for Epizyme Inc. [EPZM]. The present Moving Average for the last 50 days of trading for this stock 16.34, while it was recorded at 13.70 for the last single week of trading, and 18.01 for the last 200 days.

Epizyme Inc. [EPZM]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Epizyme Inc. [EPZM] shares currently have an operating margin of -744.29. Epizyme Inc.’s Net Margin is presently recorded at -715.53.

Return on Total Capital for EPZM is now -56.92, given the latest momentum, and Return on Invested Capital for the company is -54.99. Return on Equity for this stock declined to -60.37, with Return on Assets sitting at -48.25. When it comes to the capital structure of this company, Epizyme Inc. [EPZM] has a Total Debt to Total Equity ratio set at 17.59. Additionally, EPZM Total Debt to Total Capital is recorded at 14.96, with Total Debt to Total Assets ending up at 13.54. Long-Term Debt to Equity for the company is recorded at 18.80, with the Long-Term Debt to Total Capital now at 14.18.

Reflecting on the efficiency of the workforce at the company, Epizyme Inc. [EPZM] managed to generate an average of -$838,892 per employee. Receivables Turnover for the company is 1.96 with a Total Asset Turnover recorded at a value of 0.07.Epizyme Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 14.70 and a Current Ratio set at 14.80.

Earnings per share (EPS) analysis for Epizyme Inc. [EPZM] stock

With the latest financial reports released by the company, Epizyme Inc. posted -0.4/share EPS, while the average EPS was predicted by analysts to be reported at -0.53/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 24.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EPZM. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Epizyme Inc. go to 38.00%.

Epizyme Inc. [EPZM]: Insider Ownership positions

There are presently around $1,136 million, or 96.20% of EPZM stock, in the hands of institutional investors. The top three institutional holders of EPZM stocks are: PRIMECAP MANAGEMENT CO/CA/ with ownership of 13,564,581, which is approximately -0.692% of the company’s market cap and around 0.60% of the total institutional ownership; RP MANAGEMENT, LLC, holding 9,166,667 shares of the stock with an approximate value of $112.75 million in EPZM stocks shares; and REDMILE GROUP, LLC, currently with $107.85 million in EPZM stock with ownership of nearly 0.257% of the company’s market capitalization.

Positions in Epizyme Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 78 institutional holders increased their position in Epizyme Inc. [NASDAQ:EPZM] by around 7,054,545 shares. Additionally, 71 investors decreased positions by around 6,507,314 shares, while 15 investors held positions by with 78,766,808 shares. The mentioned changes placed institutional holdings at 92,328,667 shares, according to the latest SEC report filing. EPZM stock had 27 new institutional investments in for a total of 1,110,085 shares, while 19 institutional investors sold positions of 1,667,079 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *



Download Free eBook For


100% free. stop anytime no spam



Download Free eBook For


100% free. stop anytime no spam